FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Applied Therapeutics NDA Denied Approval

[ Price : $8.95]

FDA issues Applied Therapeutics a complete response letter on its NDA for govorestat and its use for treating classic galactosemia...

FDA OKs Mentor's Larger Breast Implants

[ Price : $8.95]

FDA approves a Mentor Worldwide PMA for its MemoryGel Enhance Breast Implants for reconstruction breast surgery in post-mastectomy...

Circulating Tumor DNA Use Guidance

[ Price : $8.95]

FDA publishes a guidance to help sponsors planning to use circulating tumor DNA as a biomarker in some cancer trials.

Patheon Italia FDA-483 Out

[ Price : $8.95]

FDA releases the form FDA-483 with four observations from a 2023 inspection at the Monza, Italy-based Patheon Italia sterile drug ...

Follow-up Testing for Ames-Positive Drugs Guide

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Recommended Follow-up Testing for an Ames-Positive Drug (Ac...

Guide on Assessing Ovarian Toxicity

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Assessment of Ovarian Toxicity in Premenopausal Adults Duri...

Oncologic Drugs Advisory Committee Renewal

[ Price : $8.95]

Federal Register notice: FDA renews its Oncologic Drugs Advisory Committee for an additional two years.

8 GDUFA Science and Research Priorities

[ Price : $8.95]

FDA identifies eight broad areas for the GDUFA FY 2025 science and research priorities.

PTC Trial in ALS Patients Misses Endpoint

[ Price : $8.95]

PTC Therapeutics says its utreloxastat failed to meet the primary endpoint in a Phase 2 ALS study and development will not continu...

FDA Alert on Skysona Hematologic Malignancies

[ Price : $8.95]

FDA issues an alert about serious adverse event reports associated with Bluebird Bios Skysona (elivaldogene autotemcel), a gene th...